期刊
MEDICINAL RESEARCH REVIEWS
卷 42, 期 3, 页码 1111-1146出版社
WILEY
DOI: 10.1002/med.21872
关键词
Auranofin; cancer; drug resistance; NF-kB inhibition; proteasome inhibition; thioredoxin reductase inhibition
Auranofin, an oral gold(I) compound originally developed for rheumatoid arthritis, is now being investigated for oncological applications with potential antineoplastic activity. Studies have shown that Auranofin can be used as a single drug or in combination with other molecules to enhance anticancer effects or overcome chemoresistance. In addition to inhibiting thioredoxin reductase, Auranofin has been found to affect other interesting targets and pathways in different cancer types.
Auranofin is an oral gold(I) compound, initially developed for the treatment of rheumatoid arthritis. Currently, Auranofin is under investigation for oncological application within a drug repurposing plan due to the relevant antineoplastic activity observed both in vitro and in vivo tumor models. In this review, we analysed studies in which Auranofin was used as a single drug or in combination with other molecules to enhance their anticancer activity or to overcome chemoresistance. The analysis of different targets/pathways affected by this drug in different cancer types has allowed us to highlight several interesting targets and effects of Auranofin besides the already well-known inhibition of thioredoxin reductase. Among these targets, inhibitory-kappa B kinase, deubiquitinates, protein kinase C iota have been frequently suggested. To rationalize the effects of Auranofin by a system biology-like approach, we exploited transcriptomic data obtained from a wide range of cell models, extrapolating the data deposited in the Connectivity Maps website and we attempted to provide a general conclusion and discussed the major points that need further investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据